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Progressive fibrosing interstitial lung diseases (PF-ILD) have poor prognosis and survival, and their 
pathogenesis is not well understood[1]. Mechanistically, lung fibrosis is thought to result from 
distorted wound-healing following tissue insults and inflammation, leading to scar formation by 
excess deposition of extracellular matrix proteins and destruction of lung architecture[2]. The 
fibrotic process is complex, and CD4+ T cells are likely involved by their production of a wide 
range of cytokines and growth factors that promote fibroblast proliferation and differentiation, 
collagen production, and stimulate production of pro-fibrotic mediators by tissue macrophages[3]. 
However, CD4+ T cells in PF-ILD are poorly characterized. To this end, we performed a detailed 
analysis of phenotype, cytokine production and clonality of T cells from the lungs [bronchoalveolar 
lavage (BAL)] of PF-ILD patients. We found that BAL from PF-ILD lungs contained high numbers 
of clonally expanded CD4+ T cells that produced an unusual combination of interferon (IFN)  and 
pro-fibrotic interleukin (IL)-13. Such cells were not found in patient blood or in control BAL 
samples.
Materials and Methods 
Subjects 
This cross-sectional study included a cohort of: (i)44 consecutive patients with PF-ILD [mean(SD) 
age 67(6)] referred for multidisciplinary diagnostic evaluation and (ii)14 control patients, aged 
50(13) without ILD (data collection: year 2015-2019). The controls underwent bronchoscopy with 
BAL>6 months after resection of carcinoid tumor, and considered healthy with no lung diseases. 7 
patients with PF-ILD had also signs of emphysema. Contraindications for bronchoscopy were 
FVC<50% predicted and/or DLCO<40% predicted. Exclusion criteria were age>75 years, anti-
fibrotic treatment, infections and active smoking during the last year. 30 patients with PF-ILD and 2 
control patients were ex-smokers. 
 
BAL and Peripheral blood mononuclear cells (PBMC) 
 
 
BAL was performed with the patient in supine position and the bronchoscopy wedged in a middle 
lobe segment (Instillation;3×40 mL Ringer solution, 37°C). Recoveries of the second and third 
aliquot were used for the cell analysis. BAL was filtered (pore size;48μm), and processed[4]. 
PBMC were prepared using Lymphoprep (STEMCELL Technologies).   
Flowcytometric cytokine analysis 
Cells from BAL and PBMC were treated as described[5]. Briefly, cells were stimulated with 
PMA/Ionomycin for 3.5h, stained for surface and intracellular antigens, acquired on a BD 
LSRFortessa (BD Bioscience), and FlowJo (LLC, Oregon) for analysis. CD4+ T cells were gated as 
CD3+/CD8 since surface CD4 expression is reduced by PMA/Ionomycin stimulation[6].  Analysis 
of untreated cells showed that >90% of the CD3+/CD8 T cells were CD4+. Cells were stained 
with anti-IFNγ Alexa488, anti-IL-10 BV421, anti-IL-17 BV421, anti-IL-13 PE, anti-CD3 PECy7, 




MACS Cytokine secretion assay (MiltenyiBiotec) was used to identify IFNγ and IL-13 producing 
viable cells for T cell receptor (TCR) single-cell clonality analysis [anti-IFNγ APC and anti-IL-13 
PE (MiltenyiBiotec), anti-CD3 PECy7 and anti-CD8 PerCP/Cy5.5], and sorted on a BD 
FACSAriaIII.  TCR sequencing were carried out as described[7]. The average TCRαβ sequencing 
efficiency was 77% (59-78) [median (range)] of which half were paired TCRαβ sequences. 
 
Ethics 
Approval: Regional Committee for Medical Research Ethics (2013/2358). Written informed 




Statistical comparisons were performed using Mann Whitney or t-tests when appropriate (SPSS 
V26). Degree of clonal expansion was described by Diversity50 (D50) (Larger D50 shows larger 
diversity and less clonality)[7]. 
 
Results 
Following multi-disciplinary evaluation, 44 patients were diagnosed with IPF (n=32), HP (n=8) or 
unclassifiable PF-ILD (n=4). Patients with PF-ILD had reduced lung function compared to controls 
[mean (SD) FVC % predicted 78(15) vs 106(17) and DLCO % predicted 50(8) vs 87(14), p<0.001].  
Many T cell cytokines may drive tissue fibrosis, including IL-10, IL-13, IL-17 and IFNγ[8]. Thus, 
cytokine production of lung T cells from BAL was assessed after short-term stimulation with 
PMA/ionomycin followed by intracellular cytokine staining (Figure 1a). No significant differences 
of IL-10+
 
and IL-17+ CD4+ T cells between PF-ILD and controls were detected, [median (IQR)] 5% 
(4-6) and 4% (3-9) for IL-10 and 5% (3-7) and 9% (4-12) for IL-17, respectively.  In contrast, BAL 
CD4+ T cells from PF-ILD patients contained a larger fraction of IL-13 producing T cells compared 
to controls, and the majority of these co-expressed IFNγ (Figure 1b). T cells co-expressing IL-13 
and IFNγ were not detectable in PBMC from patients or controls. Compiled analyses of BAL CD4+ 
IL-13+/IFNγ+ cells showed a median of 8% (IQR 3-17) in PF-ILD. This was more than 4-fold 
higher than the controls [2% (2-4)].   
To assess clonal expansion, single-cell TCRαβ sequencing was performed in BAL cells in four 
randomly selected patients with final diagnosis IPF (n=2), unclassifiable PF-ILD (n=1) and HP 
(n=1). The analysis showed that 28-80% IL-13+/IFNγ+ cells expressed identical TCR sequences 
indicating clonal expansion (Figure 1c). Identical TCR sequences were observed in IL-13/IFNγ+ 
cells, but the degree of clonal expansion was lower (17-59%) than in IL-13+/IFNγ+ cells. The IL-
13+/IFNγ+ T cells had the smallest diversity with D50 of 0.29 (average), compared to IL-




We describe a highly unusual phenotype of CD4+ T cells in BAL of PF-ILD patients, which co-
express both the Th1-associated cytokine, IFNγ, and pro-fibrotic Th2-associated cytokine, IL-13. 
Such cells were not present in patients’ blood and were hardly detectable in BAL from non-fibrotic 
controls. These distinct T cells had undergone clonal expansion probably due to local antigenic 
stimulation, and may be specifically related to pathogenic processes in the lungs of PF-ILD patients. 
To our knowledge, T cells with such “dual” phenotype have not previously been described in 
humans. However, chronic IL-18 stimulation of T cells may induce production of IL-13 in 
combination with IFNγ[9, 10]. Importantly, in mice such Th1/Th2-cells drive a pathogenic cascade 
characterized by airway hyper-responsiveness, lung inflammation and lung fibrosis[10, 11]. Earlier 
studies have shown increased levels of IL-13 in the lungs in patients with PF-ILD[2], and it is thus 
tempting to speculate that the lung-associated IL-13+/IFNγ+ CD4+ T cells that we have identified 
may be important in the pathogenesis. In the present study the IL-13+/IFNγ+ CD4+ T cells display 
characteristics of tissue resident memory T cells (Trm) by being present in BAL-samples, but 
undetectable in peripheral blood of PF-ILD patients.  However, markers to directly identify lung 
CD4+ Trm are lacking[12]. Moreover, it is unclear to what extent T cells obtained by BAL reflect 
the cellular profiles of the lung parenchyma [13]. Future efforts should therefore be directed at 
assessing if the IL-13+/IFNγ+ CD4+ T cells are bona fide Trm, their anatomical location, and 
whether they are amenable to depletion from the tissue.  
In human diseases, clonally expanded tissue resident memory T cells may promote chronic 
inflammation[14]. Earlier studies analyzing bulk preparations of BAL T cells with a panel of 
with lung fibrosis[15]. Here we directly show by single cell analysis of paired TCR sequences that 
IL-13+/IFNγ+ CD4+ T cells exhibit a high degree of clonal expansion indicating that they have 
 
 
expanded due to local antigenic stimulation. Repeated antigen stimulation may lead to 
downregulation of CD28 in T cells. Increased numbers of CD28
null
 T cells in blood may predict 




 T cells from lung explants revealed no 
increase of such cells in IPF compared to control [17], further analysis should assess whether IL-
13+/IFNγ+ CD4+ T cells display this phenotype. 
 
There is a need for better treatment options in PF-ILD, and our identification of a novel, clonally 
expanded population of lung-associated T cells with a distinct phenotype indicates a potential value 
of targeting these cells for therapeutic purposes. Future efforts to disentangle their antigenic 
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Figure 1: a1-3) Cytokine production of alveolar (BAL) CD4+ T cells.  Representative plots showing the 
gating strategy of BAL T cells, pre-gated with viability dye, following 3.5h stimulation with 
PMA/ionomycin in the presence of secretion blockade (stimulated). Cells cultured without PMA/ionomycin 
are shown as unstimulated. Progressive fibrosis interstitial lung disease (PF-ILD), non-fibrotic control (Ctr). 
(a1) CD4+ T cells were gated CD3+ and CD8 cells, and stained for (a2) IL-10, IL-17 and IFNγ or (a3-4) 
IL-13 and IFNγ. a4) Identically treated PBMCs from a representative ILD-patient are shown. b) Compiled 
percentages of T cells (BAL) expressing IL-13 and IFNγ are shown (scatter, median (IQR) between PF-ILD 
and Ctr. c) Distribution of TCR (T cell receptor)-αβ clonotypes obtained by single-cell TCR sequencing of T 
cells in BAL from 4 patients, as well as number of clonotypes and cells for IFNγ+/IL13+, IFNγ+/IL13 and 
IFNγ/IL13 CD4+ T cells. Expanded clonotypes observed in 2 cells or more are plotted as stacked boxes in 
the percentage of the total number of cells. Idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis 
(HP). 
  
 
 
 
  
